Published in Nat Rev Neurol on January 20, 2017
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis (SCRIPT) | NCT03661125
New Therapeutic Strategies for Lewy Body Dementias. Curr Neurol Neurosci Rep (2017) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol (2003) 4.76
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med (1999) 2.88
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology (2000) 2.80
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet (2013) 2.71
Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology (2014) 2.44
Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain (2000) 2.23
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2009) 2.10
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord (2006) 2.04
Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord (2012) 1.98
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 1.85
Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. Mov Disord (2015) 1.81
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67
Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behav Brain Sci (2005) 1.65
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol (2005) 1.61
Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology (1998) 1.58
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
Epidemiology of psychosis in Parkinson's disease. J Neurol Sci (2009) 1.51
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord (2008) 1.48
Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain (2013) 1.46
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations. Mov Disord (2007) 1.39
The apolipoprotein E epsilon 4 allele increases the risk of drug-induced hallucinations in Parkinson's disease. Clin Neuropharmacol (1999) 1.39
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37
The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord (2008) 1.34
Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology (2001) 1.34
Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol Psychiatry (2014) 1.32
Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain (2002) 1.27
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
Decomposing the neural correlates of antisaccade eye movements using event-related FMRI. Cereb Cortex (2007) 1.22
Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry (1999) 1.22
A profile of neuropsychiatric problems and their relationship to quality of life for Parkinson's disease patients without dementia. Parkinsonism Relat Disord (2007) 1.20
Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord (2005) 1.19
Visual hallucinatory syndromes and the anatomy of the visual brain. Brain (2000) 1.18
Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain (2009) 1.15
Hallucinations in Parkinson disease. Nat Rev Neurol (2009) 1.13
Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry (2004) 1.09
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry (2002) 1.09
Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain (2011) 1.07
Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord (2011) 1.05
Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol (2008) 1.05
The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord (2010) 1.05
Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord (2002) 1.05
Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology (2004) 1.05
Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry (2009) 1.02
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology (2009) 1.02
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology (2007) 1.01
Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology (2005) 1.00
Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord (2010) 1.00
Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology (2014) 1.00
Visual symptoms in Parkinson's disease and Parkinson's disease dementia. Mov Disord (2011) 0.99
Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol (2007) 0.99
Psychosis in Alzheimer's disease. Biol Psychiatry (2013) 0.99
A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease. BMC Neurol (2008) 0.99
Prevalence of psychotic symptoms in a community-based Parkinson disease sample. Am J Geriatr Psychiatry (2012) 0.98
The hodology of hallucinations. Cortex (2008) 0.98
Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr (2008) 0.97
Visual hallucinations in PD and Lewy body dementias: old and new hypotheses. Behav Neurol (2013) 0.97
Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry (1998) 0.96
Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol (2010) 0.96
Visual hallucinations in eye disease. Curr Opin Neurol (2009) 0.96
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology (2003) 0.96
Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain (2014) 0.95
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol (2004) 0.95
Attention and visual dysfunction in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.95
Visual hallucinations in Parkinson's disease: clues to separate origins. J Neurol Sci (2006) 0.95
Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord (2007) 0.94
Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol Sci (2002) 0.94
Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. J Neurol Neurosurg Psychiatry (2011) 0.94
Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov Disord (2010) 0.94
A semi-structured interview to assess visual hallucinations in older people. Int J Geriatr Psychiatry (2008) 0.93
The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum Brain Mapp (2013) 0.93
Phenotypic associations of tau and ApoE in Parkinson's disease. Neurosci Lett (2007) 0.93
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol (2006) 0.92
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol (2001) 0.92
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain (2009) 0.92
Hallucinators find meaning in noises: pareidolic illusions in dementia with Lewy bodies. Neuropsychologia (2014) 0.92
Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry (2015) 0.92
Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord (2008) 0.91
A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat (2009) 0.91
Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology (1990) 0.91
The default mode network is disrupted in Parkinson's disease with visual hallucinations. Hum Brain Mapp (2014) 0.90
Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease. Pharmacogenetics (2003) 0.90
Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Relat Disord (2005) 0.90
Visual hallucinatory syndromes: past, present, and future. Dialogues Clin Neurosci (2007) 0.90
Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease. Mov Disord (2010) 0.88
Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet (1999) 0.88
Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord (2006) 0.87
Visual hallucinations in Parkinson's disease: theoretical models. Mov Disord (2014) 0.87
Cerebral basis of visual hallucinations in Parkinson's disease: structural and functional MRI studies. J Neurol Sci (2011) 0.87
The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J Neurol (2011) 0.87
Structural and functional neuroimaging in patients with Parkinson's disease and visual hallucinations: A critical review. Parkinsonism Relat Disord (2015) 0.86
Tricks of the mind: Visual hallucinations as disorders of attention. Prog Neurobiol (2014) 0.86
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry (1998) 0.86
Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord (2008) 0.86
Cognitive decline in Parkinson disease. Nat Rev Neurol (2017) 0.77